JP2007507428A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507428A5
JP2007507428A5 JP2006528331A JP2006528331A JP2007507428A5 JP 2007507428 A5 JP2007507428 A5 JP 2007507428A5 JP 2006528331 A JP2006528331 A JP 2006528331A JP 2006528331 A JP2006528331 A JP 2006528331A JP 2007507428 A5 JP2007507428 A5 JP 2007507428A5
Authority
JP
Japan
Prior art keywords
compound according
substituted
heterocycloalkyl
unsubstituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006528331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507428A (ja
Filing date
Publication date
Priority claimed from US10/675,927 external-priority patent/US8299108B2/en
Application filed filed Critical
Publication of JP2007507428A publication Critical patent/JP2007507428A/ja
Publication of JP2007507428A5 publication Critical patent/JP2007507428A5/ja
Withdrawn legal-status Critical Current

Links

JP2006528331A 2003-09-29 2004-09-29 置換ベンズアゾールおよびRafキナーゼのインヒビターとしてのその使用 Withdrawn JP2007507428A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/675,927 US8299108B2 (en) 2002-03-29 2003-09-29 Substituted benzazoles and methods of their use as inhibitors of raf kinase
PCT/US2004/032161 WO2005032548A1 (en) 2003-09-29 2004-09-29 Substituted benzazoles and use thereof as inhibitors of raf kinase

Publications (2)

Publication Number Publication Date
JP2007507428A JP2007507428A (ja) 2007-03-29
JP2007507428A5 true JP2007507428A5 (OSRAM) 2007-08-30

Family

ID=34422104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528331A Withdrawn JP2007507428A (ja) 2003-09-29 2004-09-29 置換ベンズアゾールおよびRafキナーゼのインヒビターとしてのその使用

Country Status (13)

Country Link
US (2) US8299108B2 (OSRAM)
EP (1) EP1675584A1 (OSRAM)
JP (1) JP2007507428A (OSRAM)
KR (1) KR20060089232A (OSRAM)
CN (1) CN1913884A (OSRAM)
AU (1) AU2004277405A1 (OSRAM)
BR (1) BRPI0414908A (OSRAM)
CA (1) CA2539748A1 (OSRAM)
EA (1) EA011890B1 (OSRAM)
IL (1) IL174431A0 (OSRAM)
MX (1) MXPA06003435A (OSRAM)
WO (1) WO2005032548A1 (OSRAM)
ZA (1) ZA200603418B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
JP4755991B2 (ja) * 2003-10-16 2011-08-24 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Rafキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006078907A1 (en) * 2005-01-20 2006-07-27 Amgen Inc. 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
AU2007215247B2 (en) * 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
KR20090033904A (ko) 2006-07-21 2009-04-06 노파르티스 아게 벤즈이미다졸릴 피리딜 에테르의 제제
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
BRPI0809643A2 (pt) * 2007-04-05 2014-11-11 Daiichi Sankyo Co Ltd Derivados de heteroarila bicíclica fundida
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) * 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
US8697874B2 (en) * 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
BRPI0921862A2 (pt) * 2008-12-05 2015-12-29 Arqule Inc inibidores de raf e seus usos
BRPI1006113A2 (pt) 2009-03-05 2016-02-16 Daiichi Sankyo Co Ltd "derivado de piridina".
AU2011265254B2 (en) 2010-06-11 2016-05-19 Smith & Nephew, Inc. Patient-matched instruments
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
CN102276482A (zh) * 2011-04-11 2011-12-14 常州大学 2-甲氧基-5-溴苯胺的制备方法
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN103435554A (zh) * 2013-09-06 2013-12-11 中国药科大学 2-苯氨基苯并咪唑类化合物及其用途
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN105949178B (zh) * 2015-03-09 2020-05-26 西格莱(苏州)生物医药有限公司 一种苯并咪唑类化合物、其制备方法、中间体及应用
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
KR101770310B1 (ko) 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
EP3383852A4 (en) * 2015-11-30 2019-08-28 Children's Medical Center Corporation COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
CN106674264A (zh) * 2016-12-20 2017-05-17 苏州汉德创宏生化科技有限公司 (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
JP7094942B2 (ja) 2017-03-15 2022-07-04 住友ファーマ株式会社 ベンズイミダゾール誘導体の製造方法
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
EP3652165B1 (en) * 2017-07-12 2021-08-25 Bristol-Myers Squibb Company Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
CA3079786A1 (en) 2017-10-24 2019-05-02 The Broad Institute, Inc. 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN111788183B (zh) * 2018-02-07 2024-02-23 韩国化学硏究院 用于抑制tnik的杂环融合苯基化合物及其医疗用途
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
GEP20247648B (en) 2019-04-24 2024-07-25 Bayer Ag 4h-pyrrolo[3,2-c]pyridin-4-one compounds
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
EP3958865B1 (en) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2021198020A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
BR112022022409A2 (pt) * 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
WO2022133098A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023009708A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510991A (en) * 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
EP1218358B1 (en) * 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
DE60103136T2 (de) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation

Similar Documents

Publication Publication Date Title
JP2005529089A5 (OSRAM)
JP2007509058A5 (OSRAM)
JP2007509059A5 (OSRAM)
US12357603B2 (en) Acyl sulfonamides for treating cancer
JP6873145B2 (ja) 5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン
TWI238824B (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
AU2014331794B2 (en) Inhibitors of KRAS G12C
EP1678166B1 (en) Protein kinase inhibitors
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
CN104098551B (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
EP3268490B1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
MXPA05007990A (es) Compuestos de tienopirimidina y uso de los mismos.
CN105601619A (zh) 调控jak激酶的喹唑啉衍生物和其使用方法
CN109153640A (zh) 用抗病毒剂消除乙型肝炎病毒
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
KR20230167053A (ko) 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법
CN103874494A (zh) 使用pi3k/mtor的吡啶并嘧啶酮抑制剂与苯达莫司汀和/或利妥昔单抗治疗恶性血液病的组合疗法
TW201028422A (en) Amino-heterocyclic compounds
JP2013516393A5 (OSRAM)
JP2010502717A (ja) インターロイキン1受容体関連キナーゼの調節物質
JP2010512338A5 (OSRAM)
CA2432870A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
CZ304767B6 (cs) Substituovaný pyridin a pyridazin, farmaceutická kompozice s jeho obsahem a použití
JP2012530763A (ja) Cyp17阻害剤としての1,3−二置換イミダゾリジン−2−オン誘導体
WO2008003149A2 (en) Substituted pteridines for the treatment and prevention of viral infections